BIIB
stock Healthcare Drug Manufacturers - GeneralOverall Mixed · 50%
- Fundamentals Strong
- Trajectory Steady
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bullish 5 of 5 trend signals bullishRSI 55 — firm momentum, not yet overbought.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $195.96
- +3.78%
- Close
- $195.96
- +3.78%
- Current
- $195.96
- Prev close
- $188.83
- Today
- 876.83K
- 3-mo avg
- 1.14M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 2983 days ago
- Next expected
- Jul 30in 9 days
Recent earnings dates
- Apr 29 83 days ago
- Apr 6 106 days ago
- Feb 6 165 days ago
- Jan 14 188 days ago
Past earnings dates come from BIIB’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), BIIB’s fundamentals read as strong overall.
At 21.1x, the price is a reasonable multiple of the company's annual profit.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 13.1% margin is solid, in the ordinary range for a profitable company.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 7.1% return on equity is respectable, in the normal range.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 4.4% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 0.61, the company carries less in liabilities than in equity, a conservative balance sheet.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 2.68, short-term assets comfortably cover short-term bills.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 2.2% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income fell 20.8% from the prior year; profit is shrinking.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |
| Net income | $1.6B | $3.0B | $1.2B | $1.6B | $1.3B |
| Diluted EPS | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Dividend / share | — | — | — | — | — |
| Total assets | $23.9B | $24.6B | $26.8B | $28.0B | $29.4B |
| Total liabilities | $12.9B | $11.2B | $12.0B | $11.3B | $11.2B |
| Shareholder equity | $11.0B | $13.4B | $14.8B | $16.7B | $18.3B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.5B | $2.5B | $2.4B | $2.6B | $2.5B | $2.3B | $2.5B |
| Net income | $583.6M | $388.5M | $266.7M | $240.5M | $634.8M | $466.5M | -$48.9M | $319.5M |
| Diluted EPS | $4.00 | $2.66 | $1.82 | $1.64 | $4.33 | $3.17 | $-0.35 | $2.15 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 58d ago
- Viehbacher Christopher President and CEO · Director
- Kramer Robin Chief Financial Officer
- Alexander Susan H EVP Chief Legal Officer
- Godbout Sean Chief Accounting Officer
- Gregory Ginger EVP, Human Resources
- Grogan Jane Head of Research
- Izzar Rachid Head of Global Product Strat.
- Keeney Adam Head of Corporate Development
- Murphy Nicole Head of Pharm Ops and Tech
- Singhal Priya Head of Development
- Pangalos Menelas N Director
Officers and board are drawn from BIIB’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 14 −6.4% one-day move
- Apr 29 +6.0% one-day move
- Mar 11 Officer or director change reported in an 8-K
- Feb 11 Officer or director change reported in an 8-K
- Feb 6 +8.5% one-day move
- Jan 14 −5.0% one-day move
- Oct 1, 2025 +10.1% one-day move
- Sep 2, 2025 +5.6% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 51d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report